EMBC Robert J. Hombach bought Embecta Corp. shares — SEC Form 4BUYEmbecta Corp.

The shares are currently trading at $8.79, a 36.94% decline over the past year and 43.47% below the 52-week high of $15.55, though they are only 0.23% above the 52-week low of $8.77.

• •Q3 2026 earnings results on Aug 7, which showed a $50 million sequential revenue jump and raised adjusted EPS guidance.
• •The completion of the Owen Mumford acquisition on May 18, intended to diversify the company beyond diabetes care.
• •The signal flag indicating this is the largest purchase of Director Robert J. Hombach's career.

• •Bank of America downgraded the stock to Underperform with a $3 price target on May 24, while S&P Global cut the credit rating to 'B' from 'B+' on May 14.
• •The stock carries a short interest of 14.18% of the float.